

ENQUIRE Cluster 5, Oncology

John Bowers, Ph.D.
Director
Division of Translational and Clinical Sciences
27 September 2021

ENQUIRE Refresher (Evaluating Panel Quality in Review)

Overview of ENQUIRE Process



External Scientific Panel

- ✓ Web-published guidelines and shared interest statements
- ✓ Random sample specific aims/abstracts
- ✓ Workload (app #) data
- ✓ wRCR analysis
- ✓ Zero-publication counts



Internal Process Panel

- ✓ External Scientific Panel's report and data, plus:
- ✓ Rosters (pubs/funds)
- ✓ Scoring patterns
- ✓ ESI app/award rates
- ✓ Survey results (POs & Reviewers)
- ✓ Study section site-visit reports



Approvals

- ✓ EAWG
- ✓ **CSR Advisory Council**



CSR Implementation

- ✓ Internal discussions with staff, mock sort.
- ✓ Publish new study section and referral guidelines. Move reviewers/expertise as needed
- ✓ Monitor referral/adherence to new guidelines

External Panel

Multiple Actions for Restructuring Study Sections



Change in scientific guidelines



Merge study sections



Create new study sections



Eliminate study sections



Move an area of science from one study section to another/others



Add emerging areas of science

Cluster 5 IRGs

OBT IRG

Cancer Molecular Pathobiology Study Section (CAMP)
Cancer Etiology Study Section (CE)
Cancer Genetics Study Section (CG)
Molecular Oncogenesis Study Section (MONC)
Tumor Cell Biology Study Section (TCB)
Tumor Microenvironment Study Section (TME)
Tumor Progression and Metastasis Study Section (TPM)

BDA IRG

Drug Discovery and Molecular Pharmacology (DMP)
Developmental Therapeutics(DT)
Mechanisms of Cancer Therapeutics (MCT1)
Mechanisms of Cancer Therapeutics (MCT2)
Radiation Therapeutics and Biology Study Section (RTB)

OTC IRG

Cancer Biomarkers Study Section (CBSS)
Cancer Immunopathology and
Immunotherapy(CII)
Clinical Oncology Study Section (CONC)
Cancer Prevention Study Section (CPSS)
ZRG1 OTC (CII overflow sep)

Study Sections in Cluster 5, Oncology

1. Cancer Molecular Pathobiology (CAMP)
2. Cancer Biomarkers (CBSS)
3. Cancer Immunopathology and Immunotherapy (CII)
4. Clinical Oncology (CONC)
5. Mechanisms of Cancer Therapeutics - 1 Study Section (MCT1)
6. Mechanisms of Cancer Therapeutics - 2 Study Section (MCT2)
7. Molecular Oncogenesis (MONC)
8. Tumor Cell Biology (TCB)
9. Tumor Microenvironment (TME)
10. Tumor Progression and Metastasis (TPM)
11. ZRG1 OTC-M (CII overflow sep)

External Panel (March 2021)

11 to 13 Panels

- Immunotherapy
 - 1 study section currently, ~300 applications
 - Created 4 study sections and sprinkled area into others
- Therapeutics
 - 2 new study sections differentiated by new vs established therapeutic paradigm
- Basic Cancer Science
 - Differentiated MONC/CAMP into CGET/CPBS with nucleic acid vs protein themes. Thought cancer related structural biology and cell biology was better reviewed in cancer specific study sections.
 - Updated 3 study sections
- Other
 - CONC & CBSS updated

External Panel Study Sections

1. Basic Cancer Immunobiology (BCI)
2. Cellular Cancer Immunotherapy (CCI)
3. Translational Immuno-oncology (TIO)
4. Therapeutic Immune Regulation (TIR)
5. Cancer Genomics, Epigenomics and Transcription (CGET)
6. Cancer Protein Biochemistry and Signaling (CPBS)
7. Cancer Cell Biology (CCB)
8. Tumor Evolution, Heterogeneity and Metastasis (TEHM)
9. Tumor Host Interactions (THI)
10. Clinical Oncology (CONC)
11. Molecular Cancer Diagnosis, Classification and Systems Biology (MCDC)
12. The Mechanisms of Novel Oncotherapeutics (MENO)
13. The Mechanisms of Established Oncotherapeutics (MESO)

Internal Panel (August 2021)

- Process Aspects
 - Positive evaluations and comments from CSR site visitors, POs and reviewers. ESIs scored notably worse in one study section.
- External Panel report
 - Agreed with external panel recommendations with 2 exceptions; CGET, CPBS
 - TEHM and MCDC could be too broad
 - Suggested many clarifications to better define scope

Internal Panel Process Issue

- One study section significantly tougher on ESIs
 - Additional attention by SRO and Chief to change culture in SRG (underway).
 - Take advantage of reshuffling of members to new study sections to change SRG culture towards ESIs.

Internal Panel

Cancer Genomics, Epigenomics and Transcription (CGET)

Cancer Protein Biochemistry and Signaling (CPBS)

- Topical expansions beyond scope of cluster
- Strongly disagreed that cancer related structural biology and cell biology should be reviewed in cancer specific study sections. Better reviewed in broadly defined basic science panels rather than disease themed panels.
- Questioned separation based on transcription/translation vs protein
- CPBS may be too narrow

Proposed Changes to CGET/CPBS

- CGET: Delete genomics/genomic instability which are covered in study sections outside of the cluster. New name, Gene Regulation in Cancer (GRIC).
- CPBS: Delete straight structure/function and signaling bullets which are covered in study sections outside of the cluster, clarify overlap with basic sciences. Lessen focus on proteins. New name, Biochemical and Cellular Oncogenesis (BCO).

Additional Internal Comments

- Breadth of 2 proposed study sections; Tumor Evolution, Heterogeneity and Metastasis (TEHM) and Molecular Cancer Diagnosis, Classification and Systems Biology (MCDC)
 - Evaluate via mock sort, adjust if needed.

Name Changes

- Mechanisms of Novel Oncotherapeutics (MENO) to Mechanisms of Novel Cancer Therapeutics (MNCT)
- Mechanisms of Established Oncotherapeutics (MESO) to Mechanisms of Established Cancer Therapeutics (MECT)

CSR Proposed Study Sections

	Current	External Panel	Post-Internal *
Immunotherapy	<ul style="list-style-type: none"> Cancer Immunopathology and Immunotherapy (CII) ZRG1 OTC-M (CII overflow sep) 	<ul style="list-style-type: none"> Basic Cancer Immunobiology (BCI) Cellular Cancer Immunotherapy (CCI) Translational Immuno-oncology (TIO) Therapeutic Immune Regulation (TIR) 	<ul style="list-style-type: none"> Basic Cancer Immunobiology (BCI) Cellular Cancer Immunotherapy (CECI) Translational Immuno-oncology (TIO) Therapeutic Immune Regulation (TIR)
Basic Cancer Science	<ul style="list-style-type: none"> Cancer Molecular Pathobiology (CAMP) Molecular Oncogenesis (MONC) Tumor Cell Biology (TCB) Tumor Microenvironment (TME) Tumor Progression and Metastasis (TPM) 	<ul style="list-style-type: none"> Cancer Genomics, Epigenomics and Transcription (CGET) Cancer Protein Biochemistry and Signaling (CPBS) Cancer Cell Biology (CCB) Tumor Host Interactions (THI) Tumor Evolution, Heterogeneity and Metastasis (TEHM) 	<ul style="list-style-type: none"> Gene Regulation in Cancer (GRIC) Biochemical and Cellular Oncogenesis (BCO) Cancer Cell Biology (CCB) Tumor Host Interactions (THI) Tumor Evolution, Heterogeneity and Metastasis (TEHM)
Therapeutics	<ul style="list-style-type: none"> Mechanisms of Cancer Therapeutics - 1 (MCT1) Mechanisms of Cancer Therapeutics - 2 (MCT2) 	<ul style="list-style-type: none"> The Mechanisms of Novel Oncotherapeutics (MENO) The Mechanisms of Established Oncotherapeutics (MESO) 	<ul style="list-style-type: none"> Mechanisms of Novel Cancer Therapeutics (MNCT) Mechanisms of Established Cancer Therapeutics (MECT)
	<ul style="list-style-type: none"> Cancer Biomarkers (CBSS) Clinical Oncology (CONC) 	<ul style="list-style-type: none"> Molecular Cancer Diagnosis, Classification and Systems Biology (MCDC) Clinical Oncology (CONC) 	<ul style="list-style-type: none"> Molecular Cancer Diagnosis, Classification and Systems Biology (MCDC) Clinical Oncology (CONC)

*Study section names are tentative

CSR Advisory Council Discussion